Annexon (ANNX) Cash from Investing Activities (2019 - 2026)
Annexon (ANNX) posted quarterly Cash from Investing Activities of $27.1 million for Q1 2026, down 72.28% year-over-year from $97.6 million in Q1 2025, and up 202.02% quarter-over-quarter from -$26.5 million in Q4 2025.
Analysis
Annexon (ANNX) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Annexon's Cash from Investing Activities history runs 8 years deep, the most recent figure standing at $27.1 million for Q1 2026.
- In Q1 2026, Cash from Investing Activities fell 72.28% year-over-year to $27.1 million; the TTM figure through Mar 2026 stood at $119.5 million (up 372.34% YoY), while the FY2025 annual figure was $190.1 million, up 186.86% from the prior year.
- Cash from Investing Activities for Q1 2026 stood at $27.1 million, up from -$26.5 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $97.6 million in Q1 2025, with the low at -$96.6 million in Q2 2024.
- The 5-year median for Cash from Investing Activities is $14.1 million (2022), against an average of $7.5 million.
- The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities surged 1203.13% in 2022, then tumbled 2720.65% in 2025.
- Annexon's Cash from Investing Activities stood at -$43.6 million in 2022, then surged by 94.99% to -$2.2 million in 2023, then soared by 146.36% to $1.0 million in 2024, then sank by 2720.65% to -$26.5 million in 2025, then surged by 202.02% to $27.1 million in 2026.
- Business Quant data shows ANNX's Cash from Investing Activities at $27.1 million in Q1 2026, -$26.5 million in Q4 2025, and $45.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Annexon | 978.58 Mn | 978.58 Mn | - | 39.97 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 39.97 Mn |
| Mar 31, 2026 | 27.06 Mn |
| Dec 31, 2025 | -26.52 Mn |
| Sep 30, 2025 | 45.87 Mn |
| Jun 30, 2025 | 73.08 Mn |
| Mar 31, 2025 | 97.62 Mn |
| Dec 31, 2024 | 1.01 Mn |
| Sep 30, 2024 | -45.93 Mn |
| Jun 30, 2024 | -96.58 Mn |
| Mar 31, 2024 | -77.30 Mn |
| Dec 31, 2023 | -2.18 Mn |
| Sep 30, 2023 | 47.84 Mn |
| Jun 30, 2023 | 5.53 Mn |
| Mar 31, 2023 | 19.52 Mn |
| Dec 31, 2022 | -43.62 Mn |
| Sep 30, 2022 | 14.10 Mn |
| Jun 30, 2022 | 19.71 Mn |
| Mar 31, 2022 | 68.25 Mn |
| Dec 31, 2021 | 33.70 Mn |
| Sep 30, 2021 | -1.28 Mn |